Abstract:Background:MicroRNA- (miR-) 657 has been shown to regulate immunological and inflammatory activity, and it has also been defined to be dysregulated in both non-small-cell lung cancer (NSCLC) and hepatocellular carcinoma. The mechanistic role whereby miR-657 influences NSCLC progression, however, has yet to be clarified.Methods:miR-657 and SRCIN1 expression levels were assessed via qPCR in the cell lines and tissues of NSCLC. Besides, correlations between the levels of miR-657 and NSCLC patient pathological characteristics were examined, and the Kaplan-Meier approach was employed for the evaluation of the prognostic utility of miR-657 in these patients. Moreover, the Pearson correlation analyses and dual-luciferase reporter assessments were used for detecting interactive relationships between miR-657 and SRCIN1. In addition, CCK-8, EdU, and Transwell assessments were employed for the appraisal of the ability of miR-657/SRCIN1 to regulate NSCLC cell proliferation and invasion. Western blotting was employed for the assessment of the levels of NSCLC cell proteins associated with the epithelial-mesenchymal transition (EMT) that were influenced by miR-657. The nude mice xenograft tumor model is established to observe the effect of miR-657 on NSCLC growth in vivo.Results:NSCLC patient tissues and cell lines exhibited upregulated miR-657 expression that was closely related to tumor differentiation, lymphoid metastasis, and TNM stage. High levels of miR-657 were predictive of a poorer NSCLC patient prognosis, and overexpressing miR-657 resulted in the more rapid growth of NCI-H1650 and A549 cells, with a concomitant increase in their invasion. In addition, miR-657 overexpression raised the levels of Slug, N-cadherin, and Vimentin in these two cell lines while promoting E-cadherin downregulation. Dual-luciferase reporter assays confirmed that miR-657 was capable of binding to the SRCIN1 gene, and SRCIN1 expression levels were negatively associated with those of miR-657, indicating that it acts as a negative regulator of this gene. Knocking down SRCIN1 was capable to reverse the influences of miR-657 inhibitor treatment on NSCLC cell behavior. Finally, in vivo studies showed that miR-657 promoted NSCLC cell growth.Conclusion:The obtained findings illuminate that miR-657 can promote the growth of tumors and the induction of the EMT in NSCLC cells by targeting SRCIN1 expression and modulating Slug pathway activation, highlighting this pathway as a promising therapeutic target in cases suffering from NSCLC.

Mir-495 Promotes the Chemoresistance of SCLC Through the Epithelial-Mesenchymal Transition Via Etk/BMX.

Intensified Beclin-1 Mediated by Low Expression of Mir-30a-5p Promotes Chemoresistance in Human Small Cell Lung Cancer

Mir-145-5p Inhibits Epithelial-Mesenchymal Transition Via the JNK Signaling Pathway by Targeting MAP3K1 in Non-Small Cell Lung Cancer Cells.

A Mirna-200C/cathepsin L Feedback Loop Determines Paclitaxel Resistance in Human Lung Cancer A549 Cells in Vitro Through Regulating Epithelial–mesenchymal Transition

P2.15-010 Etk Interacting with PFKFB4 Modulates Chemoresistance of Small Cell Lung Cancer by Regulating Autophagy

MiR-200b and miR-15b regulate chemotherapy-induced epithelial-mesenchymal transition in human tongue cancer cells by targeting BMI1

miR‐4448/Girdin/Akt/AMPK axis inhibits EZH2‐mediated EMT and tumorigenesis in small‐cell lung cancer

Mir-657 Targets SRCIN1 Via the Slug Pathway to Promote NSCLC Tumor Growth and EMT Induction.

Linc00173 promotes chemoresistance and progression of small cell lung cancer by sponging miR-218 to regulate Etk expression

Tumor Invasion and Metastasis Regulated by Microrna-184 and Microrna-574-5p in Small-Cell Lung Cancer

Exosomal miR-92b-3p Promotes Chemoresistance of Small Cell Lung Cancer Through the PTEN/AKT Pathway

Mir-139-5p Inhibits the Epithelial-Mesenchymal Transition and Enhances the Chemotherapeutic Sensitivity of Colorectal Cancer Cells by Downregulating BCL2

Antagonizing Mir-455-3p Inhibits Chemoresistance and Aggressiveness in Esophageal Squamous Cell Carcinoma

Gene expression profiling of drug-resistant small cell lung cancer cells by combining microRNA and cDNA expression analysis

P2.15-009 Linc00173 Modulates Chemoresistance of Small Cell Lung Cancer by Functioning As a Competing Endogenous RNA to Regulate Etk Expression

Mir-335 Inhibits Small Cell Lung Cancer Bone Metastases Via IGF-IR and RANKL Pathways.

Mir-145 Suppresses the Proliferation, Invasion and Migration of NSCLC Cells by Regulating the BAX/BCL-2 Ratio and the Caspase-3 Cascade

The miR 495-UBE2C-ABCG2/ERCC1 axis reverses cisplatin resistance by downregulating drug resistance genes in cisplatin-resistant non-small cell lung cancer cells

Suppression of CX3CL1 by miR-497-5p inhibits cell growth and invasion through inactivating the ERK/AKT pathway in NSCLC cells

Mir-760 Mediates Chemoresistance Through Inhibition of Epithelial Mesenchymal Transition in Breast Cancer Cells.

Mir-410 Induces Both Epithelial–mesenchymal Transition and Radioresistance Through Activation of the PI3K/mTOR Pathway in Non-Small Cell Lung Cancer